Why Alnylam Pharmaceuticals Stock Was Soaring on Monday
Key Points
Two analysts weighed in with new evaluations of the biotech.
This followed last week's earnings release.
- 10 stocks we like better than Alnylam Pharmaceuticals ›
Several positive new analyst notes were the tailwinds pushing the stock of Alnylam Pharmaceuticals (NASDAQ: ALNY) higher on Tuesday. The first day of the holiday-shortened trading week saw Alnylam's share price floating more than 6% higher in late-session trading.
A new bull says buy
Of these analyses, the one authored by Ilya Zubkov of Freedom Capital Markets appeared to have the greatest impact on Alnylam stock. The pundit upgraded his recommendation on the company to buy from his previous hold, although he lowered his price target on the biotech (to $410 per share from $470).
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
The new take came mere days after Alnylam reported its fourth-quarter and full-year 2025 results. These disappointed investors, as the company missed the consensus analyst revenue estimate despite a bottom-line beat.
According to reports, Zubkov was particularly encouraged by the performance of Amvuttra, a drug that targets a heart disorder called transthyretin amyloid cardiomyopathy (ATTR-CM). In his view, sales of the medication were exceptionally robust in both the domestic and international markets, and that momentum should continue this year. He did caution, however, that pricing pressure could affect the company's key fundamentals two or three years down the road.
A very reasonable take
The Freedom Capital Markets analyst wasn't the only professional Alnylam-watcher to get more bullish on the stock. Also that morning, Canaccord Genuity's Whitney Ijem raised her price target on it to $429 per share from $415.
I continue to believe that investors were too harsh on Alnylam following its earnings release. While it's understandable that they would be disappointed by a revenue miss, Amvuttra has excellent momentum behind it and should continue to be quite the motor of growth for Alnylam. I'm siding with the bulls on this one.
Should you buy stock in Alnylam Pharmaceuticals right now?
Before you buy stock in Alnylam Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alnylam Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $414,554!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,120,663!*
Now, it’s worth noting Stock Advisor’s total average return is 884% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 17, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.
Recommended Articles
